Evidence map›Paper›PMID 32989269›Full record

ArticleGenetics in medicine : official journal of the American College of Medical Genetics2021

Identifying rare, medically relevant variation via population-based genomic screening in Alabama: opportunities and pitfalls.

Kevin M Bowling, Michelle L Thompson, David E Gray, James M J Lawlor, Kelly Williams, Kelly M East, Whitley V Kelley, Irene P Moss, Devin M Absher, E Christopher Partridge and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Genetics in medicine : official journal of the American College of Medical Genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Functional Profiling ofCirculation. Genomic and precision medicine · 2025
    Article
  2. Article
  3. Poison exon annotations improve the yield of clinically relevant variants in genomic diagnostic testing.Genetics in medicine : official journal of the American College of Medical Genetics · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kevin M BowlingHudsonAlpha Institute for Biotechnology, Huntsville, AL, USA.
Michelle L ThompsonHudsonAlpha Institute for Biotechnology, Huntsville, AL, USA.
David E GrayHudsonAlpha Institute for Biotechnology, Huntsville, AL, USA.
James M J LawlorHudsonAlpha Institute for Biotechnology, Huntsville, AL, USA.
Kelly WilliamsHudsonAlpha Institute for Biotechnology, Huntsville, AL, USA.
Kelly M EastHudsonAlpha Institute for Biotechnology, Huntsville, AL, USA.
Whitley V KelleyHudsonAlpha Institute for Biotechnology, Huntsville, AL, USA.
Irene P MossThe University of Alabama at Birmingham, Birmingham, AL, USA.
Devin M AbsherHudsonAlpha Institute for Biotechnology, Huntsville, AL, USA.
E Christopher PartridgeHudsonAlpha Institute for Biotechnology, Huntsville, AL, USA.
Anna C E HurstThe University of Alabama at Birmingham, Birmingham, AL, USA.
Jeffrey C EdbergThe University of Alabama at Birmingham, Birmingham, AL, USA.
Gregory S BarshHudsonAlpha Institute for Biotechnology, Huntsville, AL, USA.
Bruce R KorfThe University of Alabama at Birmingham, Birmingham, AL, USA.
Gregory M CooperHudsonAlpha Institute for Biotechnology, Huntsville, AL, USA. gcooper@hudsonalpha.org.ORCID http://orcid.org/0000-0001-5509-9923

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the effectiveness and specificity of population-based genomic screening in Alabama.

methodsThe Alabama Genomic Health Initiative (AGHI) has enrolled and evaluated 5369 participants for the presence of pathogenic/likely pathogenic (P/LP) variants using the Illumina Global Screening Array (GSA), with validation of all P/LP variants via Sanger sequencing in a CLIA-certified laboratory before return of results.

resultsAmong 131 variants identified by the GSA that were evaluated by Sanger sequencing, 67 (51%) were false positives (FP). For 39 of the 67 FP variants, a benign/likely benign variant was present at or near the targeted P/LP variant. Variants detected within African American individuals were significantly enriched for FPs, likely due to a higher rate of nontargeted alternative alleles close to array-targeted P/LP variants.

conclusionIn AGHI, we have implemented an array-based process to screen for highly penetrant genetic variants in actionable disease genes. We demonstrate the need for clinical validation of array-identified variants in direct-to-consumer or population testing, especially for diverse populations.

Indexed as

Genetic TestingGenomicsAlabamaGenetic VariationHigh-Throughput Nucleotide SequencingHumansclinically actionablediverse populationfalse positivegenotyping arraypopulation screening

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.